COL3A1 Overexpression Associates with Poor Prognosis and Cisplatin Resistance in Lung Cancer

Wang, Lihuai; Sun, Yifeng; Guo, Zhongcong; Liu, Hua

doi:10.4274/balkanmedj.galenos.2022.2022-6-16

Cited by 9 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, we performed gene-set enrichment analysis on the identified DE genes with MSigDB gene-sets 13, 14 , identifying significantly down-regulated pathways that are relevant to collagen, such as collagen-activated tyrosine kinase receptor signaling pathway and collagen metabolic and catabolic process (Figure 4E). Previous studies have found that the overexpression of collagen genes such as COL11A1 15 and COL3A1 16 in NSCLC may indicate poor prognosis and drug resistance, and COL1A1 is correlated with immune infiltration in NSCLC 17 . Our finding of these genes that are expressed significantly more in the tumor cells from the macrophage neighborhood than tumor cells from the stromal neighborhood can potentially lead a more detailed investigation of the biological mechanism about transcriptional changes within the context of cancer spatial TME studies.…”

Section: Resultsmentioning

confidence: 97%

hoodscanR: profiling single-cell neighborhoods in spatial transcriptomics data

Liu,

Martin,

Bhuva

et al. 2024

Preprint

View full text Add to dashboard Cite

Understanding complex cellular niches and neighborhoods are giving us new insights into tissue biology. Accurate neighborhood identification is crucial, yet existing methodologies often struggle to detect mixed neighborhoods and generate cell-specific neighborhood profiles. To address these limitations, we introduce hoodscanR, a Bioconductor package designed for neighborhood identification and downstream analyses using spatial data. Applying hoodscanR to breast and lung cancer datasets, we showcase its efficacy in conducting detailed neighborhood analyses and identify subtle transcriptional changes in tumor cells from different neighborhoods. Such analyses can help researchers gain valuable insights into disease mechanisms and potential therapeutic targets.

show abstract

Section: Resultsmentioning

confidence: 97%

hoodscanR: profiling single-cell neighborhoods in spatial transcriptomics data

Liu,

Martin,

Bhuva

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“… 23 A series of studies have cataloged the implication of deregulated proteins in drug resistance of NSCLC. 24 , 25 Previous work unveils the important role of COL3A1 in DDP resistance development of NSCLC, 15 but its regulatory factors are not fully understood. In this work, we focused on COL3A1 and found that COL3A1 expression is enhanced in DDP-resistant NSCLC.…”

Section: Discussionmentioning

confidence: 99%

“…To study the effect on DDP resistance, we also procured A549 cells with DDP resistance (A549/DDP, #CL-0519) from Procell. The H460/DDP cell line derived from H460 cell line was generated and maintained as described by Wang and colleagues 15 using DDP reagent (Selleck, Shanghai, China).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Role and mechanism of COL3A1 in regulating the growth, metastasis, and drug sensitivity in cisplatin-resistant non-small cell lung cancer cells

Ren,

Zhao,

Lai

2024

Cancer Biology & Therapy

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is among the most difficult malignancies to treat. Type III collagen (COL3A1) can affect the progression and chemoresistance development of NSCLC. We herein explored the mechanism that drives COL3A1 dysregulation in NSCLC. Potential RNA-binding proteins (RBPs) and transcription factors (TFs) that could bind to COL3A1 were searched by bioinformatics. mRNA expression was detected by quantitative PCR. Protein expression was evaluated using immunoblotting and immunohistochemistry. The effects of the variables were assessed by gauging cell growth, invasiveness, migratory capacity, apoptosis, and cisplatin (DDP) sensitivity. The direct YY1/COL3A1 relationship was confirmed by ChIP and luciferase reporter experiments. Xenograft experiments were done to examine COL3A1’s function in DDP efficacy. COL3A1 showed enhanced expression in DDP-resistant NSCLC. In H460/DDP and A549/DDP cells, downregulation of COL3A1 exerted inhibitory functions in cell growth, invasiveness, and migration, as well as promoting effects on cell DDP sensitivity and apoptosis. Mechanistically, ELAV-like RNA binding protein 1 (ELAVL1) enhanced the mRNA stability and expression of COL3A1, and Yin Yang 1 (YY1) promoted the transcription and expression of COL3A1. Furthermore, upregulation of COL3A1 reversed ELAVL1 inhibition- or YY1 deficiency-mediated functions in DDP-resistant NSCLC cells. Additionally, COL3A1 downregulation enhanced the anti-tumor efficacy of DDP in vivo. Our investigation demonstrates that COL3A1 upregulation, induced by both RBP ELAVL1 and TF YY1, exerts important functions in phenotypes of NSCLC cells with DDP resistance, offering an innovative opportunity in the treatment of drug-resistant NSCLC.

show abstract

“…COL3A1 overexpression has been discovered in multiple cancer cell types, including breast, ovarian, and colorectal cancer. 37 , 38 …”

Section: Discussionmentioning

confidence: 99%

Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Chemotherapy in Acute Myeloid Leukemia

Qu¹,

Huang²,

Guo³

et al. 2023

DDDT

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is a highly heterogenous disease with varying clinical outcomes among patients. Epithelial-mesenchymal transition (EMT) is an important mechanism underlying cancer metastasis and chemotherapy resistance. However, few EMT-based signatures have been established to predict AML prognosis and treatment efficacy. Methods By conducting comparative RNA-seq analysis, we discovered the differential expression of EMT genes between AML patients with relapse and those without relapse. Based on the prognostic analysis of the differentially expressed EMT genes, a metastasis-related EMT signature (MEMTs) was constructed. An analysis was conducted on both TARGET and TCGA cohorts to explore the possible association between MEMTs and prognosis in AML. Three separate chemotherapy treatment cohorts were utilized to assess the predictive efficacy of MEMTs for chemotherapy response. In addition, the potential correlation between MEMTs and the tumor microenvironment was also investigated. Finally, random forest analysis and functional experiments were conducted to verify the key MEMTs gene associated with AML metastasis. Results Based on expression and prognostic analysis, we constructed MEMTs that include three EMT genes (CDH2, LOX, and COL3A1). Our findings suggested that the MEMTs could act as a prognostic factor for AML patients, and furthermore, it proved to be a predictor of their response to chemotherapy. Specifically, high MEMTs was associated with worse prognosis and poor response to chemotherapy, while low MEMTs was linked to better prognosis and higher response rates. Random forest and functional experiments demonstrate that CDH2 is a key gene promoting leukemia cell metastasis among the three MEMTs genes. Conclusion The identification of MEMTs could potentially act as a predictor for the prognosis and the response to chemotherapy in AML patients. Individual tumor evaluation based on MEMTs could provide personalized treatment options for AML patients in the future.

show abstract

COL3A1 Overexpression Associates with Poor Prognosis and Cisplatin Resistance in Lung Cancer

Cited by 9 publications

References 34 publications

hoodscanR: profiling single-cell neighborhoods in spatial transcriptomics data

hoodscanR: profiling single-cell neighborhoods in spatial transcriptomics data

Role and mechanism of COL3A1 in regulating the growth, metastasis, and drug sensitivity in cisplatin-resistant non-small cell lung cancer cells

Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Chemotherapy in Acute Myeloid Leukemia

Contact Info

Product

Resources

About